Vopak : The medium term resistance level limits the upside potential
| Entry price | Target | Stop-loss | Potential |
|---|
|
€49.29 |
€46 |
€51.9 |
+6.67% |
|---|
The price of shares in Royal Vopak is close to a major medium term resistance level around 51.74 EUR. A correction phase over the short term appears to be the logical outcome.
Strengths● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The tendency within the weekly time frame is positive above the technical support level at 43.3 EUR
● According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● Revenue estimates are regularly revised downwards for the current and coming years.
● For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
VOPAK 
